晚期卵巢上皮性癌腹腔化疗的应用价值  

Clinical Value of Abdominal Chemotherapy on Advanced Epithelial Ovarian Cancer

作　　者：李新春[1] 徐宣枝[1] 周彦杰[1] 王贝蒂[1] 

机构地区：[1]湖南省肿瘤医院妇瘤科,湖南长沙410013

出　　处：《实用预防医学》2009年第4期1197-1199,共3页Practical Preventive Medicine

摘　　要：目的探讨晚期卵巢上皮性癌腹腔化疗的疗效,毒副反应及对患者长期生存的影响。方法对2000年1月-2004年1月在我院治疗的晚期卵巢上皮性癌患者184例,根据术后不同化疗途径分为静脉化疗组(IVC)和腹腔化疗组(IPC)。两组化疗方案相同:紫彬醇+顺铂。均给予6～8个疗程化疗,疗程结束后评价疗效,比较两组的毒副反应、疗效和预后。结果IPC组和IVC组有效率分别为92.6%和87.6%,两组比较差异无统计学意义(P>0.05),复发率:IPC组为48.9%,IVC组为60.3%,两组比较差异无统计学意义(P>0.05),复发时间:IPC组24个月,IVC组18个月,两组比较差异有统计学意义(P<0.05),毒副反应中化学性静脉炎发生率:IPC组为10.7%,IVC组为33.7%,两组比较差异有统计学意义(P<0.05),其他毒副反应两组间比较差异均无统计学意义。结论腹腔化疗并不能提高晚期卵巢上皮性癌的疗效,但能够延长其复发时间,临床应用时仍有一定的局限性。Objective To evaluate the efficacy and toxicity of intraperitoneal chemotherapy in advanced epithelial ovarian cancer, and its effect on prognosis of the patients. Methods Totally 184 patients with epithelial ovarian cancer who were hospitalized in our hospital from January, 2001 to January, 2004 were enrolled in this study. According to different postoperative chemotherapy approaches, all.the patients were assigned into intraperitoneal chemotherapy （IPC） group and intravenous chemotherapy （IVC） group. All the patients received TP （taxol ＋ cisplatin）, and treated with 6--8 courses of postoperative regular chemotherapy. After chemotherapy, the toxicity, therapeutic efficacy, and prognosis were evaluated and compared between the two groups. Results The response rates of IPC group and IVC group were 92.6 % and 87.6 %, respectively, no statistically significant difference was found between the two groups （P 〉0.05）. The recurrence rates of I PC group and IVC group were 48.9% and 60.3%, and the difference was not statistically significant （P〉0.05）. The time of recurrencein IPC group was 24 months after operation, and that of IVC group was 18 months; there were statistically significant differences between the two groups （P〈 0.0.5）. In IPC group and IVC group, the incidence rates of chemotherapeutic phlebitis were 10.7 % and 33.7 %, respectively; and the difference was statistically significant （P〈 0.0.5）. No statistically significant difference was found in other side effects between the two groups （P 〉 0.05）. Conclusion I PC can extend the dis, ease progression-free survival, but shows clinical restriction.

关 键 词：卵巢肿瘤 化学疗法 输注 胃肠外 静脉内 

分 类 号：R737.31[医药卫生—肿瘤]